Rosen Law Firm reminds purchasers of Erasca common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors who purchased Erasca common stock during the class period may be entitled to compensation through a contingency fee arrangement. To join the class action or seek lead plaintiff status, investors must move the Court by August 10, 2026.
Erasca IncSecurities class action lawsuit alleges false and misleading statements about drug candidate ERAS-0015, exposing company to legal and reputational risk.